Mechanism and Therapeutic Strategies of Ailamode in the Treatment of RA-induced Bone Loss

Rheumatoid arthritis (RA) caused by exceed bone absorption than osteogenesis and the subsequent osteoporosis (bone loss) around joints and in entire body, is the most commonly seen bone disease in clinic, which is induced by inlfammatory factors and corticosteroid therapies, while RA-induced bone loss is believed to be associated with the decreased osteogenesis because of the increased bone absorption and low osterix expression by reason of over-expressions of TNF-α, IL-1, Il-6 and RANKL, etc.. Ailamode (ALMD, T-614) is a new anti-RA agent (DMARDs) and a regulator for immunity and bone metabolism. Research showed that T-614 could eliminate bone absorption and up-regulate osterix expression to improve osteogenesis by inhibiting some inlfammatory factors (TNF-α, IL-1 and Il-6), so as to reduce bone and joint damages. And several clinical evidences have proved that T-614 is safe in treating RA and has synergistic effect with methotrexate (MTX), which could strengthen the efifcacy and decrease bone erosion. Therefore, it is considered to be the most valuable agent in the treatment of RA and RA-induced bone loss at present.